- Home
- DAVEW vs RVMDW Comparison
DAVEW vs RVMDW Comparison
Compare DAVEW & RVMDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVEW
- RVMDW
- Stock Information
- Founded
- DAVEW 2015
- RVMDW 2014
- Country
- DAVEW United States
- RVMDW United States
- Employees
- DAVEW 285
- RVMDW N/A
- Industry
- DAVEW Retail: Computer Software & Peripheral Equipment
- RVMDW
- Sector
- DAVEW Technology
- RVMDW
- Exchange
- DAVEW Nasdaq
- RVMDW Nasdaq
- Market Cap
- DAVEW N/A
- RVMDW N/A
- IPO Year
- DAVEW N/A
- RVMDW N/A
- Fundamental
- Price
- DAVEW $0.30
- RVMDW $0.18
- Analyst Decision
- DAVEW
- RVMDW
- Analyst Count
- DAVEW 0
- RVMDW 0
- Target Price
- DAVEW N/A
- RVMDW N/A
- AVG Volume (30 Days)
- DAVEW 46.1K
- RVMDW 15.6K
- Earning Date
- DAVEW 03-06-2025
- RVMDW 02-26-2025
- Dividend Yield
- DAVEW N/A
- RVMDW N/A
- EPS Growth
- DAVEW N/A
- RVMDW N/A
- EPS
- DAVEW 3.12
- RVMDW N/A
- Revenue
- DAVEW $319,355,000.00
- RVMDW $742,000.00
- Revenue This Year
- DAVEW N/A
- RVMDW N/A
- Revenue Next Year
- DAVEW N/A
- RVMDW N/A
- P/E Ratio
- DAVEW $34.00
- RVMDW N/A
- Revenue Growth
- DAVEW 30.00
- RVMDW N/A
- 52 Week Low
- DAVEW $0.28
- RVMDW $0.10
- 52 Week High
- DAVEW $0.32
- RVMDW $0.12
- Technical
- Relative Strength Index (RSI)
- DAVEW N/A
- RVMDW N/A
- Support Level
- DAVEW N/A
- RVMDW N/A
- Resistance Level
- DAVEW N/A
- RVMDW N/A
- Average True Range (ATR)
- DAVEW 0.00
- RVMDW 0.00
- MACD
- DAVEW 0.00
- RVMDW 0.00
- Stochastic Oscillator
- DAVEW 0.00
- RVMDW 0.00
About DAVEW Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit, and finding side gigs.
About RVMDW Revolution Medicines Inc. Warrant
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.